Alkermes Executive and Leadership Team

Blair Jackson, the Chief Executive Officer, Elect at Alkermes, directs the company's overarching strategic vision and operational execution. Overseeing all facets of the global biopharmaceutical enterprise, Blair Jackson ensures alignment with the mission to develop and commercialize innovative medicines for complex psychiatric and neurological disorders. This leadership role involves guiding the company's pursuit of treatments for conditions such as addiction, schizophrenia, and opioid dependence, integrating scientific research with clinical development and commercial infrastructure. By focusing on patient-inspired science, the Chief Executive Officer, Elect drives Alkermes' commitment to addressing serious unmet medical needs and improving the management of central nervous system diseases. The strategic direction set by Blair Jackson is critical for advancing the company's pipeline and enhancing its market impact in neuroscience.

Stephen Schiavo, the Senior Vice President and Chief Human Resources Officer at Alkermes, architects the global human capital strategy. Overseeing all aspects of talent acquisition, development, and retention, Stephen Schiavo ensures the organization possesses the specialized expertise required for biopharmaceutical innovation. This leadership position involves cultivating a culture that supports deep neuroscience expertise and patient-inspired science, critical for Alkermes' mission. By managing employee relations, compensation, and benefits, the Chief Human Resources Officer drives operational efficiency and fosters an environment conducive to addressing complex psychiatric and neurological disorders. Stephen Schiavo's focus on talent development is integral to the company's ability to deliver both marketed medicines and investigational candidates, ultimately supporting the improvement of chronic neurological and mental health condition management.

Craig Hopkinson, the Executive Vice President & Chief Marketing Officer, Research & Development at Alkermes, spearheads the strategic commercialization of the company's innovative medicines. Overseeing global marketing efforts, Craig Hopkinson ensures that Alkermes' treatments for complex psychiatric and neurological disorders reach the patients and healthcare providers who need them most. This role integrates deep neuroscience expertise with patient-focused insights to drive market penetration for conditions like addiction and schizophrenia. By developing and executing comprehensive marketing strategies, the Chief Marketing Officer, Research & Development enhances Alkermes' market position and supports the delivery of both marketed medicines and investigational candidates. The commercial leadership provided by Craig Hopkinson is vital for addressing serious unmet medical needs and improving the management of central nervous system diseases worldwide.

David Gaffin, the Senior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc., provides critical legal and ethical oversight for the global biopharmaceutical enterprise. Overseeing all legal affairs and ensuring rigorous compliance with regulatory standards, David Gaffin safeguards Alkermes' operations and its commitment to patient-inspired science. This leadership function is essential for navigating the complex regulatory landscape associated with developing treatments for psychiatric and neurological disorders, including addiction and schizophrenia. By managing corporate governance, intellectual property, and risk mitigation, the Chief Legal Officer and Chief Compliance Officer ensures the integrity of Alkermes' research, development, and commercial activities. David Gaffin's expertise is fundamental to the company's ability to deliver innovative medicines and address serious unmet medical needs responsibly.